Choosing a country will allow you to access local content and enable you to shop in your local currency.
Today, monoclonal antibodies, hormones, vaccines, and plasma proteins are on the market or in development. Their upstream production relies on genetically engineered organisms followed by downstream processes, which typically involves the use of integrated filtration and chromatography products
Once a biopharmaceutical is in production, great care must be taken to ensure consistent quality while safeguarding its efficacy and process economy. To help you meet these challenges, GE Healthcare has developed a range of products, platform technologies, and services designed to assist you with efficient and robust production.
Across the bioprocessing spectrum, our focus is on supporting you from idea to result. Imaginative minds. Inspiring science.
For information about lab-scale chromatography, go to Protein Purification.
Many factors are crucial for successful development of biosimilars and biobetters, including high quality comparability data, choice of production system and process economy.
Blood plasma is a highly complex source of vital protein products that benefit patients suffering from diseases such as antibody deficiencies and hemophilia. The removal or inactivation of pathogens such as viruses and prions, as well a high degree of purity are vital aspects of plasma fractionation.
The development of genetically engineered monoclonal antibodies (MAbs) has transformed healthcare and our ability to produce new biomedicines, but there are strong pressures to decrease manufacturing costs.
Recent decades have witnessed a large increase in the immunological and technological strategies employed for manufacturing vaccines
We've detected that you're using an unsupported browser.You may continue browsing, but for the best experience, please use Mozilla Firefox (v.30+), Google Chrome (v.35+) or Internet Explorer (v.11+).